Clinical Trial

ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings

Study acronym: ETHOS II
Recruiting
View on ClinicalTrials.gov →
Summary
The overall goals of the ETHOS II Project are to enhance hepatitis C virus (HCV) care in drug treatment clinics and needle and syringe programs (NSPs) in New South Wales and Australia, and to develop a translational framework for subsequent establishment of HCV screening and treatment programs in drug treatment clinics and NSPs across NSW and nationally.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2018-09-24; most recent amendment 2026-05-11.
Trial Details
NCT Number NCT03685045
Lead Sponsor Kirby Institute
Collaborators: National Health and Medical Research Council, Australia
Conditions Hepatitis C
Enrollment 6,000 participants
Start Date 2018-05-28
Primary Completion 2026-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-14